Orchard Therapeutics announces multiple presentations at ASGCT 2024

Orchard Therapeutics (ORTX), recently acquired by Kyowa Kirin (KYKOF) with the goal of accelerating the delivery of new gene therapies to patients around the globe, announced four oral and four poster presentations from across its hematopoietic stem cell gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT, taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel, as well as three presentations detailing neurological, skeletal, and other clinical outcomes from a proof-of-concept study of investigational OTL-203 in the Hurler subtype of mucopolysaccharidosis type I. In addition, Orchard Therapeutics will give an invited oral presentation highlighting the potential of OTL-104, a pre-clinical HSC gene therapy developed by its in-house research team, to address a severe and treatment refractory form of Crohn’s disease.